ORIGINAL RESEARCH article

Front. Chem.

Sec. Medicinal and Pharmaceutical Chemistry

Synthesis and antimicrobial activity of Sulfonyl-imidazole linked fused isoxazolo[3,4-b][1,2,3]triazolo[4,5-d]pyridines:PEG-400 mediated one-pot reaction under ultrasonic irradiation

  • 1. Department of Chemistry, Chaitanya (Deemed to be University), Hyderabad, India

  • 2. Department of Pharmaceutical Chemistry and Phytochemistry, Nirmala College of Pharmacy, Mangalagiri, India

  • 3. Department of Biotechnology, Chaitanya (Deemed to be University), Hyderabad, India

The final, formatted version of the article will be published soon.

Abstract

The rapid emergence of methicillin-resistant and vancomycin-resistant Staphylococcus aureus (MRSA and VRSA) represents a major global health challenge, necessitating the development of new antibacterial scaffolds with improved efficacy and safety. In this study, a novel series of sulfonyl-imidazole-linked fused isoxazolo [3,4-b][1,2,3]triazolo[4,5-d]pyridine derivatives (6a–6o) was synthesized using a PEG-400-mediated, ultrasound-assisted one-pot Cu(I)-catalysed strategy under environmentally benign conditions. The synthesized compounds were evaluated for antibacterial activity against MSSA, MRSA, and VRSA strains. Several derivatives exhibited potent antibacterial effects, with compound 6k emerging as the most active candidate, displaying MIC values of 1.56–3.12 µg/mL, surpassing the reference drug dicloxacillin. Selected compounds also demonstrated significant anti-biofilm activity, effectively inhibiting biofilm formation in resistant S. aureus strains. Importantly, hemolysis assays using mouse erythrocytes and cytotoxicity studies on RAW 264.7, THP-1, and BoMac cells revealed minimal hemolytic and cytotoxic effects, indicating excellent biocompatibility. Furthermore, immunomodulatory studies showed moderate and controlled cytokine induction, suggesting a balanced host immune response without excessive inflammation. Overall, this study identifies compound 6k as a promising lead with potent antibacterial, antibiofilm, and immunomodulatory properties coupled with a favorable safety profile, warranting further preclinical development against drug-resistant S. aureus infections.

Summary

Keywords

Antibacterial Agents, Antibiofilm activity, Isoxazolo-triazolopyridines, MRSA, TLR4 docking, Ultrasonication, VRSA

Received

09 January 2026

Accepted

20 February 2026

Copyright

© 2026 Premalathaa, Kapavarapu, Kavela and Narsimha. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Sridhar Kavela; Sirassu Narsimha

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Share article

Article metrics